Heparin effective and safe treatment for COVID-19
Researchers from the Australian National University, with King’s Heparin, have discovered that heparin can limit lung damage when inhaled by COVID-19 patients.
Patients with severe COVID-19 disease develop blood clots in the lungs which can be lethal. Blood thinners, such as Heparin, can prevent such clots from forming. Because the drug has antiviral properties and calms the immune system, it can be used at different stages of treatment. Indeed, treated patients included in the studies were not uniform in their COVID-19 disease severity, which suggests inhaled Heparin is safe and effective to use across the spectrum of COVID-19 disease.
The researchers found that breathing and oxygen levels improved in 70% of patients after inhaling a course of heparin.
Study lead, Professor Frank van Haren, from The Australian National University, said: “This drug is already available in hospitals all over the world and it is a very inexpensive drug. If it is as effective as our early results suggest, it could have a major impact in our fight against COVID.”
He added: “It also works as an anti-inflammatory drug; the medicine has the ability to calm everything down when the body is mounting an exaggerated response to the virus. We already know heparin can reduce lung damage caused by this inflammation and the immune response overdrive that we see in other lung diseases which could provide benefit to patients hospitalised with COVID-19.
He added: “There is no other drug that has these three different effects: anti-viral, anti-inflammatory and anti-coagulant...Most COVID experts agree that vaccination alone is not going to stop the pandemic. This could really assist in poorer countries where vaccination is challenging and we think it could help front line workers who could use it as a preventative measure.”
The findings are published in the British Journal of Clinical Pharmacology.
Other News
Featured Supplier
MMM has been operating worldwide as one of the leading system providers in the service of health since 1954. With a full portfolio of products and services pertaining to sterilization & disinfection systems for hospitals, scientific institutes, laboratories & the pharmaceutical industry, MMM has positioned itself as a crucial quality driver.
Upcoming Events
BSG LIVE 22
ICC, Birmingham
20th – 23rd June 2022
EBME Expo 2022
Coventry Building Society Arena, Phoenix Way, Rowleys Green, Coventry CV6 6GE
28th - 29th June
Infection 360: What's trending in infection prevention & control
Edgbaston Stadium, Birmingham
27-28 September 2022
IP2022 IS COMING TO BOURNEMOUTH IN OCTOBER 2022
Bournemouth
17-19 October 2022
UKHCA Conference: Listen Up
Pendulum Hotel and Manchester Conference Centre, Manchester
3rd November 2022
MEDICA 2022
Dusseldorf Germany
14th November - 17th November
Access the latest issue of Clinical Services Journal on your mobile device together with an archive of back issues.
Download the FREE Clinical Services Journal app from your device's App store
